Why A Lexicon Deal for Sota Feels Like Momentum Is Building
Following the EMPEROR-Preserved and FIGARO-DKD data readouts at ESC 2021, it seems as if a deal for Lexicon’s sotagliflozin should be building momentum. Below, FENIX provides thoughts on the quickly evolving HF/CKD market and insight into what a potential deal for sotagliflozin may look like, despite some caveats.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.